Synthaverse SA (SVEP)

Currency in PLN
2.940
-0.080(-2.65%)
Closed·
SVEP is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.9003.020
52 wk Range
2.6005.080
Key Statistics
Bid/Ask
2.935 / 2.94
Prev. Close
3.02
Open
2.96
Day's Range
2.9-3.02
52 wk Range
2.6-5.08
Volume
71.41K
Average Volume (3m)
55.98K
1-Year Change
-40%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SVEP Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Short term obligations exceed liquid assets

Synthaverse SA News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Earnings

Latest Release
Jun 03, 2026
EPS / Forecast
-0.05 / --
Revenue / Forecast
14.05M / 12.8M
EPS Revisions
Last 90 days

SVEP Income Statement

Compare SVEP to Peers and Sector

Metrics to compare
SVEP
Peers
Sector
Relationship
P/E Ratio
−9.7x−3.9x−0.4x
PEG Ratio
0.020.050.00
Price/Book
1.8x2.9x2.6x
Price / LTM Sales
5.3x3.8x3.0x
Upside (Analyst Target)
-42.5%48.7%
Fair Value Upside
Unlock8.6%5.6%Unlock

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents for use in oncology, gynecology, hematology, immunology, and related therapeutic areas in Poland, the rest of the European Union, and internationally. The company operates through the BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anti-D 50 and GAMMA anti-D 150, which are human anti-rh0(d) immunoglobulin products used in the prevention of maternal-fetal conflict in terms of the D antigen with the Rh system; GAMMA anty HBs 200 medications for use in passive prophylaxis hepatitis B virus; and BCG 10 tuberculosis vaccines. It also provides Distreptaza, a medication for chronic ovarian inflammation and hemorrhoidal disease; LAKCID, which is a lactobacillus probiotic drug; and pseudocholinoesteraza, which is a laboratory reagent. In addition, the company engages in the contract production of injection drugs, lyophilisates of active substances in sterile sealed vials, active substances and drugs based on surface and submerged biological culture, and suppository forms of drugs. The company was formerly known as BIOMED-LUBLIN Wytwórnia Surowic i Szczepionek S.A. and changed its name to Synthaverse S.A. in July 2023. Synthaverse S.A. was founded in 1944 and is headquartered in Lublin, Poland.

Employees
214
Market
Poland

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
1.17K0.00%3.45K
Other Institutional Investors
21.05M27.78%61.88M
Public Companies & Retail Investors
54.72M72.22%160.88M
Total
75.77M100.00%222.77M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
AgioFunds Towarzystwo Funduszy Inwestycyjnych S.A.6.86%5,195,00015,273
OPDF S.A.6.71%5,083,39914,945

People Also Watch

257.00
CRQP
+6.20%
119.90
ASBP
+6.01%
31.49
ZAB
+0.61%
96.10
NWGP
0.00%
99.20
CMP
-2.75%

FAQ

What Is the Synthaverse (SVEP) Stock Price Today?

The Synthaverse stock price today is 2.940 PLN.

What Stock Exchange Does Synthaverse Trade On?

Synthaverse is listed and trades on the Warsaw Stock Exchange.

What Is the Stock Symbol for Synthaverse?

The stock symbol for Synthaverse is "SVEP."

What Is the Synthaverse Market Cap?

As of today, Synthaverse market cap is 222.770M PLN.

What Is Synthaverse's Earnings Per Share (TTM)?

The Synthaverse EPS (TTM) is -0.312.

When Is the Next Synthaverse Earnings Date?

Synthaverse will release its next earnings report on Sep 02, 2026.

From a Technical Analysis Perspective, Is SVEP a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has Synthaverse Stock Split?

Synthaverse has split 0 times.

How Many Employees Does Synthaverse Have?

Synthaverse has 214 employees.

What is the current trading status of Synthaverse (SVEP)?

As of Aug 08, 2026, Synthaverse (SVEP) is trading at a price of 2.940 PLN, with a previous close of 3.020 PLN. The stock has fluctuated within a day range of 2.900 PLN to 3.020 PLN, while its 52-week range spans from 2.600 PLN to 5.080 PLN.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.